See more : UCB SA (UCBJY) Income Statement Analysis – Financial Results
Complete financial analysis of Alnylam Pharmaceuticals, Inc. (ALNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alnylam Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Amal Ltd (AMAL.BO) Income Statement Analysis – Financial Results
- Peako Limited (PKO.AX) Income Statement Analysis – Financial Results
- Otis Worldwide Corp (4PG.DE) Income Statement Analysis – Financial Results
- Chengdu KSW Technologies Co.,Ltd. (688283.SS) Income Statement Analysis – Financial Results
- NISSO PRONITY Co., Ltd. (3440.T) Income Statement Analysis – Financial Results
Alnylam Pharmaceuticals, Inc. (ALNY)
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
Cost of Revenue | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.80M | 13.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.52B | 868.60M | 704.14M | 414.80M | 194.69M | 73.11M | 76.55M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
Gross Profit Ratio | 83.02% | 83.73% | 83.40% | 84.16% | 88.60% | 97.59% | 85.13% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
Research & Development | 1.00B | 883.02M | 792.16M | 654.82M | 655.11M | 505.42M | 390.64M | 382.39M | 276.50M | 190.25M | 112.96M | 86.57M | 99.30M | 106.38M | 108.73M | 96.88M | 120.69M | 49.80M | 35.32M | 24.60M | 13.10M | 3.34M |
General & Administrative | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 7.53M | 880.00K |
Other Expenses | 0.00 | -109.37M | -2.05M | 45.53M | 20.73M | 4.17M | -3.02M | 6.17M | 76.00K | 1.82M | -47.00K | 331.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
Cost & Expenses | 2.11B | 1.82B | 1.55B | 1.32B | 1.16B | 889.58M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
Interest Income | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 14.41M | 15.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 121.22M | 155.97M | 143.02M | 84.50M | 0.00 | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 872.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 54.05M | 44.47M | 47.57M | 34.77M | 17.18M | 6.44M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.82M | 3.12M | 2.44M | 838.00K | 36.00K |
EBITDA | -258.24M | -926.56M | -661.56M | -736.33M | -868.08M | -754.24M | -488.19M | -409.46M | -276.96M | -172.29M | -82.71M | -51.71M | -49.69M | -38.06M | -41.02M | -18.93M | -75.06M | -35.69M | -38.83M | -29.55M | -19.61M | -4.19M |
EBITDA Ratio | -14.12% | -86.22% | -83.99% | -156.46% | -427.50% | -1,115.02% | -556.20% | -900.33% | -720.27% | 72.29% | -197.05% | -23.29% | -65.60% | -50.45% | -47.38% | -23.62% | -174.50% | -131.57% | -705.58% | -691.61% | -8,507.39% | 0.00% |
Operating Income | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M | -296.01M | -404.98M | -92.94M | -129.46M | -54.82M | -44.07M | -48.11M | -27.84M | -93.18M | -39.50M | -43.47M | -32.26M | -25.06M | -4.22M |
Operating Income Ratio | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | -1,087.56% | -556.20% | -900.33% | -720.27% | -800.97% | -197.05% | -194.01% | -66.24% | -44.05% | -47.86% | -28.95% | -183.07% | -146.68% | -760.53% | -754.18% | -14,236.93% | 0.00% |
Total Other Income/Expenses | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54.00M | 9.21M | 14.48M | 5.94M | 4.38M | 1.02M | 12.87M | -2.83M | 1.07M | 1.10M | 2.31M | 12.96M | 4.89M | 558.00K | -390.00K | -4.64M | 0.00 |
Income Before Tax | -433.52M | -1.13B | -852.14M | -855.60M | -885.25M | -760.67M | -490.87M | -410.11M | -290.07M | -400.60M | -91.92M | -116.59M | -57.65M | -43.00M | -47.01M | -25.53M | -80.22M | -34.61M | -42.91M | -35.37M | -29.69M | 0.00 |
Income Before Tax Ratio | -23.71% | -108.63% | -100.93% | -173.60% | -402.85% | -1,015.48% | -545.95% | -869.63% | -705.83% | -792.32% | -194.88% | -174.73% | -69.66% | -42.98% | -46.76% | -26.55% | -157.61% | -128.51% | -750.77% | -826.72% | -16,871.59% | 0.00% |
Income Tax Expense | 6.73M | 4.16M | 680.00K | 2.68M | 863.00K | 823.00K | -25.60M | -23.44M | -24.91M | -40.21M | -2.70M | -10.57M | -5.80M | 514.00K | 582.00K | 719.00K | 5.25M | -4.89M | -558.00K | 390.00K | 4.59M | -86.00K |
Net Income | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M | -290.07M | -360.40M | -89.23M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
Net Income Ratio | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1,016.58% | -545.95% | -869.63% | -705.83% | -712.79% | -189.17% | -158.88% | -69.66% | -43.50% | -47.34% | -27.30% | -167.92% | -128.51% | -750.77% | -763.30% | -14,223.30% | 0.00% |
EPS | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
EPS Diluted | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
Weighted Avg Shares Out | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
Weighted Avg Shares Out (Dil) | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
![News image](https://images.financialmodelingprep.com/news/alnylam-pharmaceuticals-inc-investigated-by-shareholder-rights-advocates-investors-20240307.jpg)
Alnylam Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ALNY
![News image](https://images.financialmodelingprep.com/news/alnylam-pharmaceuticals-inc-alny-investors-with-losses-are-urged-20240307.jpg)
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
![News image](https://images.financialmodelingprep.com/news/alnylam-alny-roches-blood-pressure-drug-meets-study-goal-20240306.jpg)
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
![News image](https://images.financialmodelingprep.com/news/alnylam-pharmaceuticals-inc-alny-shareholders-may-have-been-affected-20240306.jpg)
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
![News image](https://images.financialmodelingprep.com/news/roche-alnylam-say-blood-pressure-drug-succeeds-in-midstage-20240305.jpg)
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
![News image](https://images.financialmodelingprep.com/news/alnylam-reports-positive-kardia2-topline-study-results-demonstrating-clinically-20240305.jpg)
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
![News image](https://images.financialmodelingprep.com/news/alnylam-pharmaceuticals-inc-investigation-levi-korsinsky-investigates-potential-securities-20240305.jpg)
Alnylam Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alnylam (ALNY)
![News image](https://images.financialmodelingprep.com/news/levi-korsinsky-reminds-shareholders-of-an-investigation-into-alnylam-pharmaceuticals-20240303.jpg)
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud Allegations
![News image](https://images.financialmodelingprep.com/news/levi-korsinsky-reminds-shareholders-of-an-investigation-into-alnylam-20240303.jpg)
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud Allegations
![News image](https://images.financialmodelingprep.com/news/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-20240303.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Source: https://incomestatements.info
Category: Stock Reports